ERBB2 and neoplasm: A large, randomized, placebo-controlled phase III study investigating the efficacy of a HER2-related peptide, nelipepimut-S (NP-S) plus GM-CSF vaccine, recruited patients with node positive, HER2 low expressing tumours in the adjuvant setting, and although well tolerated, it resulted in no difference in disease-free survival [101].